Study of the correlation between H-ras mutation and primary hepatocellular carcinoma

Sui,Guode; Ma,Xuexiao; Liu,Shiguo; Niu,Haitao; Dong,Qian

doi:10.3892/ol.2012.832

October 2012 Volume 4 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2012 Volume 4 Issue 4

Full Size Image

Article

Study of the correlation between H-ras mutation and primary hepatocellular carcinoma

Authors:
- Guode Sui
- Xuexiao Ma
- Shiguo Liu
- Haitao Niu
- Qian Dong
View Affiliations / Copyright

Affiliations: Department of Emergency General Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Spinal Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Gout Laboratory, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Urology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China, Department of Pediatric Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, P.R. China
Pages: 779-782
|
Published online on: July 27, 2012

https://doi.org/10.3892/ol.2012.832
Expand metrics +

Abstract

The aim of this study was to investigate the correlation between H-ras mutation and primary hepatocellular carcinoma (HCC) and to describe the role of H-ras mutation in carcinogenesis. Clinical samples of 69 patients were collected and the expression levels of H-ras in HCC and the surrounding normal tissues were examined using HotStarTaq PCR. H-ras mutation was further analyzed using the PCR direct sequencing method. The results showed that H-ras mutation was present in 49 samples (49/69, 71.01%), of which 19 had codon 40 mutated from CTA to CTG and 30 had codon 61 mutated from GGC to AGC. By contrast, only 2 mutations were found in the normal tumor-adjacent tissues. The H-ras mutation rate in the high-risk of metastatic recurrence group was markedly higher than that in the low-risk group (P<0.01). The H-ras mutation rate in patients with metastatic recurrence during postoperative follow-up was also significantly higher than that in patients without metastatic recurrence (P<0.01). Based on the above results, the H-ras mutation frequency in cancer tissues is markedly higher compared with that in normal tissues. H-ras mutation may play an important role in the genesis and development of HCC and may serve as a reliable marker for individual comprehensive therapy in HCC.

View Figures

View References

1.	JM LukAM LiuProteomics of hepatocellular carcinoma in Chinese patientsOMICS15261266201110.1089/omi.2010.009921348761
2.	T YangJ ZhangJH LuLQ YangGS YangMC WuWF YuA new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohortJ Cancer Res Clin Oncol137739750201110.1007/s00432-010-0935-320607551
3.	M DaviesSS PrimeJW EvesonN PriceA GanapathyA D’MelloIC PatersonTransforming growth factor-β enhances invasion and metastasis in Ras-transfected human malignant epidermal keratinocytesInt J Exp Pathol931481562012
4.	Y Gus-BrautbarD JohnsonL ZhangH SunP WangS ZhangL ZhangYH ChenThe anti-inflammatory TIPE2 is an inhibitor of the oncogenic RasMol Cell45610618201210.1016/j.molcel.2012.01.00622326055
5.	JH OvermeyerWA MalteseDeath pathways triggered by activated Ras in cancer cellsFront Biosci1616931713201110.2741/381421196257
6.	JM CullenC WilliamsL ZadroznyJT OtstotGG SolomonRC SillsHH HongH-ras consensus sequence and mutations in primary hepatocellular carcinomas of lemurs and lorisesVet Pathol48868874201110.1177/030098581038852621123858
7.	XD ZhouRecurrence and metastasis of hepatocellular carcinoma: progress and prospectsHepatobiliary Pancreat Dis Int13541200214607620
8.	S ReginaJ RollinC BléchetS IochmannP ReverdiauY GruelTissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutationJ Thorac Oncol3689697200810.1097/JTO.0b013e31817c1b21
9.	Q ZuoH HuangM ShiF ZhangJ SunJ BinY LiaoW LiaoMultivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinomaAnat Rec (Hoboken)295423431201210.1002/ar.21531
10.	MJ HoenerhoffI ChuD BarkanZY LiuS DattaGP DimriJE GreenBMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastasesOncogene2830223032200910.1038/onc.2009.16519543317
11.	HW LoTargeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomasCurr Cancer Drug Targets10840848201010.2174/15680091079335797020718706
12.	G BuhrmanC O’ConnorB ZerbeBM KearneyR NapoleonEA KovriginaS VajdaD KozakovEL KovriginC MattosAnalysis of binding site hot spots on the surface of Ras GTPaseJ Mol Biol413773789201110.1016/j.jmb.2011.09.01121945529
13.	M NakamuraJ KitauraY EnomotoY LuK NishimuraM IsobeK OzakiY KomenoF NakaharaT OkiTransforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras/Raf signaling: Implications for tumorigenesisCancer Sci10326332012
14.	M LeeDifferential physiological effects of Raf-1 kinase pathways linked to protein kinase C activation depending on the stimulus in v-H-ras-transformed cellsCancer Res Treat403944200810.4143/crt.2008.40.2.39
15.	X YinBH ZhangSJ QiuZG RenJ ZhouXH ChenY ZhouJ FanCombined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosisAnn Surg OncolMar272012(Epub ahead of print)

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Study of the correlation between H-ras mutation and primary hepatocellular carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles